Investor

Brandon Capital's Medical Research Commercialisation Fund

Life science investment collaboration in Australia and New Zealand, now called Brandon BioCatalyst

Science
Medical
United States
New Zealand, United States
+7 more

Visit Website Get introducedRequest an introduction Write a Review

Brandon Capital's Medical Research Commercialisation Fund cover

TrustList summary

Brandon Capital's Medical Research Commercialisation Fund, or MRCF, is a life science investment collaboration for Australia and New Zealand. In 2022 it was renamed Brandon BioCatalyst. It is managed by Brandon Capital, a life science venture investor.

What the fund does

Early to expansion funding: supports life science companies from proof of concept through to commercialisation.
Translation expertise: Brandon Capital guides research discoveries towards commercial products.
Co-investment capacity: investors can invest alongside the funds, giving extra room to support portfolio companies.

Customers and markets

The collaboration links more than 50 medical research institutes and hospitals in Australia and New Zealand with superannuation funds and government bodies. Investors and venture partners come from Australia, New Zealand, the United States and the United Kingdom. The aim is to turn promising discoveries into new treatments and better patient outcomes.

Key facts

Founded: 2007, in Melbourne
Founders: Chris Nave, Stephen Thompson and David Fisher
Portfolio: helped form and fund over 50 life science companies
Offices: Australia, New Zealand, London and San Francisco

Summary written by TrustList from the business's own published information, Oct 2026.

Gallery

2 images - click to enlarge

Rankings

Brandon Capital's Medical Research Commercialisation Fund is ranked on 6 TrustList rankings: #4 on 1, #8 on 1, #9 on 1, #12 on 1, #16 on 1 and #27 on 1.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. Brandon Capital's Medical Research Commercialisation Fund has no reviews yet and 2 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Investor · 6 rankings

On 2 of these it sits behind Hps Investment Partners, Llc, ahead of Greencoat Capital.

#4of 17
United states
It is the only one of the 17 here listing biotech and science.
Its profile: “Investors and venture partners come from Australia, New Zealand, the United States and the United Kingdom.”
Of the 17 here, 6 also cover series and 5 also cover FinTech; 4 also work in Silicon Valley and 4 also work in London.
Behind Oceanwood Capital Management, ahead of 3M New Ventures.
#8of 8
Melbourne
It is the only one of the 8 here listing early stage and medical.
Of the 8 here, 3 also cover series a and 2 also cover seed stage; 7 also work in Sydney and 4 also work in New York City.
Behind Prosper Women Entrepreneurs.
#9of 21
Sydney
It is one of 2 here listing seed stage and one of 4 here listing partners.
Of the 21 here, 4 also cover partners and 3 also cover biotech; 11 also work in Dubai and 10 also work in Tokyo.
#12of 52
Biotech investors
It is one of 7 here listing early stage and one of 9 here listing medical.
Of the 52 here, 14 also cover healthtech and 11 also cover science; 15 also work in Boston and 10 also work in San Francisco.
Behind Outlander Labs, ahead of Lightstone Ventures.
#16of 199
Seed stage
It is one of 2 here listing medical and one of 3 here listing science.
Of the top 56 here, 24 also cover pre seed and 11 also cover growth stage; 4 also work in Bangalore.
Behind Quest Venture Partners, ahead of TechAviv Founder Partners.
#27of 153
London
It is one of 3 here listing medical and one of 4 here listing early stage.
Of the top 59 here, 8 also cover artificial intelligence; 12 also work in Hong Kong and 10 also work in Toronto.